Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Novel Therapeutic Targets of Prostate Cancer
share announcement

Novel Therapeutic Targets of Prostate Cancer

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: closed (15 December 2021) | Viewed by 6626

Special Issue Editor

Dr. Guillaume Ploussard

E-Mail Website
Guest Editor
Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France
Interests: prostate cancer

Special Issue Information

Dear Colleagues,

The management of advanced prostate cancer has largely evolved during the last decade. Several new drugs have been demonstrated to be life-prolonging, even in the setting of metastatic castration-resistant prostate cancer. Future research focuses on different molecular pathways, such as PTEN loss or DNA repair defects, and has potential for near-future applications. New horizons have also opened in the era of immunotherapy and PARP inhibitors. Several trials are ongoing to assess the oncologic efficacy and safety of new molecules, alone or in combination. Radioligand therapy also emerged as a promising therapeutic option, following the impressive progress of new generation imaging modalities. All these treatments are changing the paradigms in advanced prostate cancer treatment.

This Special Issue will publish up-to-date data on novel therapeutic targets in prostate cancer management.

Dr. Guillaume Ploussard
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • androgen receptor
  • immunotherapy
  • radioligands
  • theranostics
  • chemotherapy
  • PARP inhibitors

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 288 KiB  
Article
Prostate-Specific Antigen and Testosterone Levels as Biochemical Indicators of Cognitive Function in Prostate Cancer Survivors and the Role of Diabetes
by Alicja Popiołek, Bartosz Brzoszczyk, Piotr Jarzemski, Aleksandra Chyrek-Tomaszewska, Radosław Wieczór, Alina Borkowska and Maciej Bieliński
J. Clin. Med. 2021, 10(22), 5307; https://doi.org/10.3390/jcm10225307 - 15 Nov 2021
Cited by 2 | Viewed by 1550
Abstract
Prostate cancer (PC) is one of the most common malignancies in men. The increase in the number of PC survivors is associated with many problems including cognitive impairment. Early detection of such problems facilitates timely protective intervention. This study examined the association between [...] Read more.
Prostate cancer (PC) is one of the most common malignancies in men. The increase in the number of PC survivors is associated with many problems including cognitive impairment. Early detection of such problems facilitates timely protective intervention. This study examined the association between prostate-specific antigen (PSA) or testosterone (T) levels and cognitive function in patients undergoing radical prostatectomy. Such a correlation could help identify patient groups at risk of cognitive impairment. Participants underwent clinical (demographic data, medical history, physical examination, and blood analyses) and neuropsychological assessment (cognitive test battery). Preoperative PSA or T levels were not associated with cognitive function. However, long-term follow-up after prostatectomy showed a strong correlation between PSA levels and the results of verbal memory and executive function tests. A trend toward significance was also observed for visuospatial memory. The levels of free T and total T were not correlated with cognitive function. Only the levels of free T after hormonal treatment were significantly correlated with executive functions. Comorbid diabetes affected these correlations. In conclusion, PSA levels at a distant postoperative time and free T level after hormonal treatment may be biomarkers of cognitive function. Full article
(This article belongs to the Special Issue Novel Therapeutic Targets of Prostate Cancer)

Review

Jump to: Research

10 pages, 485 KiB  
Review
Overview of the Development and Use of Akt Inhibitors in Prostate Cancer
by Anis Gasmi, Guilhem Roubaud, Charles Dariane, Eric Barret, Jean-Baptiste Beauval, Laurent Brureau, Gilles Créhange, Gaëlle Fiard, Gaëlle Fromont, Mathieu Gauthé, Alain Ruffion, Raphaële Renard-Penna, Paul Sargos, Morgan Rouprêt, Guillaume Ploussard and Romain Mathieu
J. Clin. Med. 2022, 11(1), 160; https://doi.org/10.3390/jcm11010160 - 29 Dec 2021
Cited by 14 | Viewed by 2079
Abstract
Deregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been [...] Read more.
Deregulation of the PI3K-Akt-mTOR pathway plays a critical role in the development and progression of many cancers. In prostate cancer, evidence suggests that it is mainly driven by PTEN loss of function. For many years, the development of selective Akt inhibitors has been challenging. In recent phase II and III clinical trials, Ipatasertib and Capivasertib associated with androgen deprivation therapies showed promising outcomes in patients with metastatic castration-resistant prostate cancer and PTEN-loss. Ongoing trials are currently assessing several Akt inhibitors in prostate cancer with different combinations, at different stages of the disease. Full article
(This article belongs to the Special Issue Novel Therapeutic Targets of Prostate Cancer)
►▼ Show Figures

Figure 1

12 pages, 436 KiB  
Review
Potential Targets Other Than PSMA for Prostate Cancer Theranostics: A Systematic Review
by Mathieu Gauthé, Paul Sargos, Eric Barret, Gaëlle Fromont-Hankard, Jean-Baptiste Beauval, Laurent Brureau, Gilles Créhange, Raphaële Renard-Penna, Charles Dariane, Gaëlle Fiard, Romain Mathieu, Guilhem Roubaud, Alain Ruffion, Morgan Rouprêt, Guillaume Ploussard and on behalf of the CC-AFU
J. Clin. Med. 2021, 10(21), 4909; https://doi.org/10.3390/jcm10214909 - 24 Oct 2021
Cited by 3 | Viewed by 2393
Abstract
Background: Prostate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have already been [...] Read more.
Background: Prostate-specific membrane antigen (PSMA) is not sufficiently overexpressed in a small proportion of prostate cancer (PCa) patients, who require other strategies for imaging and/or treatment. We reviewed potential targets other than PSMA for PCa theranostics in nuclear medicine that have already been tested in humans. Methods: We performed a systematic web search in the PubMed and Cochrane databases, with no time restrictions by pooling terms (“prostate cancer”, “prostatic neoplasms”) and (“radioligand”, “radiotracer”). Included articles were clinical studies. The results were synthetized by the target type. Results: We included 38 studies on six different targets: gastrin-releasing peptide receptors (GRPRs) (n = 23), androgen receptor (n = 11), somatostatin receptors (n = 6), urokinase plasminogen activator surface receptor (n = 4), fibroblast activation protein (n = 2 studies) and integrin receptors (n = 1). GRPRs, the most studied target, has a lower expression in high-grade PCa, CRPC and bone metastases. Its use might be of higher interest in treating earlier stages of PCa or low-grade PCa. Radiolabeled fibroblast activation protein inhibitors were the most recent and promising molecules, but specific studies reporting their interest in PCa are needed. Conclusion: Theranostics in nuclear medicine will continue to develop in the future, especially for PCa patients. Targets other than PSMA exist and deserve to be promoted. Full article
(This article belongs to the Special Issue Novel Therapeutic Targets of Prostate Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop